Acquiring Company
argenx
Acquired Company
Forte Biosciences
AmsterdamBiotechnologyHealth CareTherapeuticsDescription
argenx completed the acquisition of Forte Biosciences, Inc. through a cash tender offer, purchasing all outstanding shares at $77.00 each. This merger enables argenx to enhance its portfolio with FB102, a first-in-class antibody. Following the merger, Forte became a wholly owned subsidiary of argenx.
Don't miss argenx's next move
Get an email the moment argenx makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Forte Biosciences?
Forte Biosciences was acquired by argenx, based in Amsterdam. The deal was reported on August 27, 2026. argenx is a global immunology innovation company focused on developing therapies for patients with severe autoimmune diseases. argenx is privately held and operates in Biotechnology.
When did argenx acquire Forte Biosciences?
argenx's acquisition of Forte Biosciences was reported on August 27, 2026. argenx completed the acquisition of Forte Biosciences, Inc. through a cash tender offer, purchasing all outstanding shares at $77.00 each. This merger enables argenx to enhance its portfolio with FB102, a first-in-class antibody. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Forte Biosciences do?
Forte Biosciences is the company acquired in this transaction. It is publicly traded (FBRX).
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.